Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.75 CAD | 0.00% | -2.86% | +20.25% |
Apr. 08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
Mar. 14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.25% | 111M | |
+14.88% | 69.91B | |
+5.62% | 8.32B | |
+5.20% | 8.07B | |
-20.43% | 7.97B | |
+0.73% | 4.56B | |
+16.98% | 4.31B | |
-2.00% | 3.99B | |
-2.89% | 3.87B | |
+21.87% | 3.63B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Brief: Says Completed Negotiations with pCPA for Vascepa